

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

Brilliant Violet 510(TM) anti-mouse/human CD44

RRID:AB_2650923

Type: Antibody

Proper Citation

BioLegend Cat# 103044, RRID:AB_2650923

Antibody Information

URL: http://antibodyregistry.org/AB_2650923

Proper Citation: BioLegend Cat# 103044, RRID:AB_2650923

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_2650923

Vendor: BioLegend

Catalog Number: 103044

Alternative Catalog Numbers: 103043

Record Creation Time: 20250820T000454+0000

Record Last Update: 20250820T071903+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 510(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Perkins B, et al. (2026) Dnmt3a-dependent de novo DNA methylation enforces lineage commitment and preserves functionality of memory Th1 and Tfh cells. *Cell reports*, 45(3), 117062.

Menezes-Silva L, et al. (2026) Hormonal rewiring of immunity during dietary restriction ensures host defense and systemic glucose conservation. *Immunity*, 59(3), 700.

Jacobs KA, et al. (2026) Autophagy maintains high endothelial venule identity and function during inflammation. *Immunity*.

Zhu L, et al. (2026) Bach2 antagonizes leukotriene B4-Ltb4r1-JunB signaling to constrain Tfh13 cell differentiation. *Cell reports*, 45(4), 117220.

Miakicheva S, et al. (2026) LEF1 and niche factors determine T cell stemness across chronic diseases. *Cell*, 189(14), 4325.

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. *Cancer cell*, 44(6), 1218.

Hammoudi A, et al. (2026) Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses. *EBioMedicine*, 127, 106269.

Schweihofer V, et al. (2025) Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma. *Frontiers in oncology*, 15, 1622008.

Henriques-Oliveira L, et al. (2025) Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity. *Immunity*.

Yang Z, et al. (2025) A mosaic H3 subtype live attenuated influenza vaccine elicits broad immune responses to influenza A viruses. *Vaccine*, 65, 127776.

Kaufmann U, et al. (2025) Transcription factor Zfx regulates tumor's evasion to T cell killing in immunotherapy. *iScience*, 28(11), 113842.

Labiano S, et al. (2025) Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas. *Cell reports. Medicine*, 6(7), 102204.

Barandun N, et al. (2025) Targeted localization of the mother centrosome in CD8+ T cells undergoing asymmetric cell division promotes memory formation. *Cell reports*, 44(1), 115127.

Kastner AL, et al. (2025) Durable lymphocyte subset elimination upon a single dose of AAV-delivered depletion antibody dissects immune control of chronic viral infection. *Immunity*, 58(2), 481.

Chen L, et al. (2025) CD94/NKG2A-Qa-1b axis as a key modulator of vaccine responsiveness in aging populations. *Cell reports*, 44(11), 116514.

Humblin E, et al. (2025) The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells. *Immunity*, 58(8), 1966.

Cabrera-Martinez B, et al. (2025) A hypomorphic *Il2rb* mutant mouse model recapitulates and reveals mechanisms of human T cell immune dysregulation in IL-2R γ deficiency. *Cell reports*, 44(7), 115902.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Bruss C, et al. (2024) Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative - specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy. *Frontiers in immunology*, 15, 1355130.

Wang Y, et al. (2024) A pan-family screen of nuclear receptors in immunocytes reveals ligand-dependent inflammasome control. *Immunity*, 57(12), 2737.